The UPMC Enterprises Translational Sciences team was created with the vision of developing and commercializing cutting-edge research and therapeutics to further the innovation of transformative medicines. With this goal in mind, the team has formed five companies in the past two years, including BlueSphere Bio and Generian, and most recently invested in Werewolf Therapeutics.
To further grow this portfolio, the Translational Sciences team at UPMC Enterprises will be investing $1 billion by 2024 to develop new drugs, diagnostics, and devices.
With the support of UPMC leadership, the Translational Sciences team, led by Jeanne Cunicelli, will be looking globally for investments and partners that complement the scientific and commercial work already underway in Pittsburgh.
For more information please read more in the press release.
Meet the Executive: Wendy Zellner, Vice President of Public Relations at UPMC
At UPMC, Zellner helps to oversee UPMC’s roughly 15-person media group (covering UPMC and Pitt Schools of the Health Sciences), and personally works with UPMC’s Enterprises, International, Information Services, and Quality divisions to identify and tell the organizations’ best stories to the media.
Comprehensive Genetic Sequencing in Clinical Care: How to Get it Right
At UPMC, we are committed to building a health system where the right patient gets the right care, in the right way, at the right time, every time. The “Rights” of clinical management…